Pardon our appearance!

We are still working on the integration of this blog into our web site, so the content is a bit ahead of our graphic appearance.

Hedge Funds…Not Looking so Pharma Smart

Just a couple of days ago, Reuters reported that Pfizer “…is winning attention from some of the savviest hedge funds thanks to high-tech drugs and vaccines that it got when it paid $68 billion for Wyeth.” OK, I get it that it’s all about THE PIPELINE and buying Wyeth put quite a few new [...]

Fixing Pharma Pride…Where is the Leadership?

The first step in making positive change is to create the mindset that one can achieve great things or surmount great challenges. I know we have seen enough evidence of this in recent months as the new U.S. administration seeks to assume a global leadership role, as well as fix the U.S. economic, energy, [...]

Is Health Care Reform Bad for Pharma?

Many have argued that health care reform in the US is a significant threat to pharma, largely due to the expectation that health care reform will certainly equate to some form of price control by the government that will dramatically reduce reimbursement for pharma products.  For many years, the public has railed over the price [...]

Flavor of the Month or Tranformational Opportunity?

Fixing Pharma.   For years, perhaps for decades, the doom and gloom about pharma’s decline has always lurked just around the corner…price controls, me-too products, and unsustainable healthcare costs always threatened.   For those of us who have been in the trenches seeking the holy grail… a robust pipeline, that is… there has always been another [...]